Sorrento rejects $1B buyout bid from unnamed private equity firm

Shares in Sorrento fell following news of the latest rejection of a takeover. (designer 491 iStockPhoto)

Sorrento Therapeutics has rejected a takeover offer from an unidentified private equity fund. News of the original bid sparked a surge in Sorrento’s sagging stock price, but the board has ruled the offer undervalues the biotech.

California-based Sorrento flew high during the biotech boom of 2015 on the back of a deal that gave Patrick Soon-Shiong’s NantHealth rights to a nanoparticle formulation of paclitaxel. Sorrento quickly fell from that high, though, and has never come close to regaining the lost ground, starting 2020 with a share price just above $3.

A private equity group apparently thought Sorrento was worth significantly more than that. Earlier this month, Sorrento revealed it had received a buyout offer of up to $7 a share, a price that would translate into a deal worth upward of $1 billion.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

However, the board of directors at Sorrento has rejected the offer, arguing it “significantly undervalues the company and is not in the best interest of the shareholders.” The exact terms of the offer remain private, making it impossible to gauge whether the bid was likely to total $7 a share or a lower amount covered by the “up to” part of Sorrento’s statement.

The rejection comes months after Sorrento knocked back offers of between $3 and $5 a share from “two biopharmaceutical companies.” On that occasion, the board also unanimously rejected the bids on the grounds they undervalued the company. 

Shares in Sorrento fell following news of the latest rejection but remain above the price they traded at at the start of the year and well above the level they languished at before news of the dismissals of the $3 to $5 offers emerged. That improvement in Sorrento’s share price, which was below $2 in November, could benefit the biotech if it moves to strengthen its balance sheet.

Sorrento ended September with $34.6 million in cash and equivalents, down from $158.7 million at the start of 2019, and $356.5 million of long term debt. The biotech could add to its cash reserves by closing one of the “multiple potential strategic alliances and transactions” it told investors it is pursuing, but it equally may need to raise more money.

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.